Ranibizumab
- Generic Name
- Ranibizumab
- Brand Names
- Byooviz, Cimerli, Lucentis, Susvimo, Ranivisio, Rimmyrah, Ximluci
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 347396-82-1
- Unique Ingredient Identifier
- ZL1R02VT79
- Background
Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment directed against human vascular endothelial growth factor A (VEGF-A), which is a glycoprotein implicated in the pathophysiology of age-related macular degeneration. Ranibizumab is used to treat various ocular disorders with abnormal growth of blood vessels, such as neovasc...
- Indication
Ranibizumab injection for intravitreal use is indicated to treat Neovascular (wet) Age-related Macular Degeneration (AMD), macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization.
...
- Associated Conditions
- Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), Macular Edema, Myopic Choroidal Neovascularization, Neovascular Age-Related Macular Degeneration (nAMD)
- Associated Therapies
- -
Triple Therapy - PDT Plus IVD and Intravitreal Ranibizumab Versus Lucentis Monotherapy to Treat Age-Related Macular Degeneration
- Conditions
- Interventions
- First Posted Date
- 2006-10-19
- Last Posted Date
- 2010-05-27
- Lead Sponsor
- Bay Area Retina Associates
- Target Recruit Count
- 60
- Registration Number
- NCT00390208
- Locations
- 🇺🇸
Georgia Retina, Riverdale, Georgia, United States
🇺🇸Bay Area Retina Associates, Walnut Creek, California, United States
🇺🇸Retina Vitreous Associates, Toledo, Ohio, United States
Lucentis (Ranibizumab) for Eales' Disease
- First Posted Date
- 2006-10-06
- Last Posted Date
- 2019-06-11
- Lead Sponsor
- Oregon Health and Science University
- Target Recruit Count
- 1
- Registration Number
- NCT00384449
- Locations
- 🇺🇸
Casey Eye Institute, Portland, Oregon, United States
Ranibizumab in Idiopathic Parafoveal Telangiectasia (RIPT) Trial
- First Posted Date
- 2006-09-19
- Last Posted Date
- 2012-11-14
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 10
- Registration Number
- NCT00378196
- Locations
- 🇺🇸
The Wilmer Eye Institute at Johns Hopkins, Baltimore, Maryland, United States
Ranibizumab in Hemorrhagic Choroidal Neovascularization Trial
- First Posted Date
- 2006-08-15
- Last Posted Date
- 2012-10-19
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 7
- Registration Number
- NCT00363168
- Locations
- 🇺🇸
The Wilmer Eye Institute at Johns Hopkins, Baltimore, Maryland, United States
SUSTAIN - Study of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
- Conditions
- Interventions
- First Posted Date
- 2006-05-31
- Last Posted Date
- 2011-02-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 531
- Registration Number
- NCT00331864
- Locations
- 🇨🇭
Novartis - 64 sites in 11 countries, Basel, Switzerland
Study of Ranibizumab Administered in Conjunction With Photodynamic Therapy With Verteporfin in Patients With Subfoveal Choroidal Neovascularization and Age-Related Macular Degeneration
- Conditions
- First Posted Date
- 2006-02-08
- Last Posted Date
- 2008-06-19
- Lead Sponsor
- Novartis
- Registration Number
- NCT00288561
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
Safety and Efficacy of Ranibizumab in Japanese Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration
- Conditions
- Interventions
- First Posted Date
- 2006-01-31
- Last Posted Date
- 2011-02-24
- Lead Sponsor
- Novartis
- Target Recruit Count
- 88
- Registration Number
- NCT00284089
- Locations
- 🇯🇵
Novartis, Tokyo, Japan
Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome
- Conditions
- First Posted Date
- 2004-08-13
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- National Eye Institute (NEI)
- Target Recruit Count
- 5
- Registration Number
- NCT00089765
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.